TXMD · TherapeuticsMD, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements.”View the 10-Q filed Aug 11, 2026
Key customers — 100% of revenue (the three and six months ended June 30, 2026)
“For the three and six months ended June 30, 2026, 100% of license revenue related to Mayne Pharma, Theramex and Knight.”
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on May 9, 2022; bars on opposite sides are not compared.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TXMD
this stock
TherapeuticsMD, Inc.
|
$23.84M | +26.4% | +35.3% | — | 0.3% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.06B | +16.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.91B | +3.3% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.98B | -1.1% | — | — | 0.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on May 9, 2022; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TXMD | -0.5% | +0.0% | -8.0% | +1.5% | +26.4% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +0.9% | -3.6% | -19.6% | -1.0% | +14.1% |